Mexiletina em um Recém-Nascido com Síndrome do QT Longo Tipo 3: Quando o Acesso se Impõe à Urgência

Pereira, Eduardo Nolla Silva; Sacilotto, Luciana; Pessente, Gabrielle D’Arezzo; Guirao, Cinthya; Carvalho, Mariana; Pereira, Alexandre da Costa; Darrieux, Francisco; Scanavacca, Maurício

doi:10.36660/abc.20210533

Search citation statements

Order By: Relevance

Paper Sections

Select...

Use Of Mexiletine In Pediatric Diseases1

Citation Types

Supporting

Mentioning

Contrasting

Year Published

2024

Publication Types

Select...

Article1

Relationship

Self Cite0

Independent1

Authors

Journals

Cited by 1 publication

(1 citation statement)

References 9 publications

(14 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…15,16 Several case studies have reported utility as early as the neonatal period. [17][18][19][20][21][22][23] Efficacy is superior in long QT syndrome type 3 due to sodium channel involvement, and mexiletine is now recommended by the European Society of Cardiology in the management of QT syndrome type 3, 9,24 but some resistant forms linked to mutation types have also been reported. 14,25 Overall, very good safety is reported, with fewer adverse gastrointestinal and neurological effects than in adults.…”

Section: Use Of Mexiletine In Pediatric Diseasesmentioning

confidence: 99%

Use of Mexiletine in Children: A Minireview

Sarret,

Barrière,

Remerand

et al. 2024

Journal of Pediatric Neurology

View full text Add to dashboard Cite

Mexiletine is well-established sodium channel blocker that acts on cardiac myocytes and neurons. It has recently been repositioned as an orphan drug in the treatment of rare neuromuscular diseases in adults with nondystrophic myotonia. It has also long been used in some rare pediatric diseases in the areas of cardiopathy, epilepsy, neuromuscular diseases, and pain disorders. Here, we review the different uses of mexiletine reported in pediatrics, stating indications, efficacy, and tolerance. Special attention by health authorities to maintain access to mexiletine in rare pediatric diseases and further pediatric research in these rare syndromes are required.

show abstract